HIMS vs HNGE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HNGE is the larger of the two ($9.80B market cap): the incumbent the market prices for continued execution (37.32x forward earnings). HIMS is the smaller challenger ($4.52B), priced similarly on forward earnings (39.14x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

HIMS vs HNGE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHIMSHNGEWhat it tells you
Market cap$4.52B$9.80BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E39.1437.32Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range20% of range96% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book12.7832.81How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how HIMS and HNGE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HIMS and HNGE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HIMS and HNGE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Hims & Hers Health (HIMS) do?

Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products on a subscription basis. Its categories span sexual health, hair loss and dermatology, mental health, and weight management, and the model is built on recurring monthly revenue: most customers are subscribers who refill automatically, which is why the company reports subscriber counts and revenue per subscriber as core metrics. It earns money primarily through these subscriptions and increasingly through higher-priced specialty offerings, and it has invested in owning more of its supply chain, including affiliated pharmacies and a lab and peptide facility.

Full HIMS guide

What does Hinge Health (HNGE) do?

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

HIMS vs HNGE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • HIMS drivers: Recurring subscription model; Category expansion beyond the original niche.
  • HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026 and about 64 percent (adjusted) in the second quarter. For HNGE, digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health.

HIMS or HNGE: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HIMS if you believe its drivers more; HNGE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HIMS and HNGE guides.

HIMS vs HNGE: the full fundamentals

HIMS. With trailing net income negative, the trailing P/E is not meaningful, and at about $6.8 billion (as of October 2026) the market values Hims at roughly 2.6 times trailing sales and about 40 times forward earnings estimates. Analysts expect a loss of about $0.56 per share for 2026 and a return to profit (~$0.42) in 2027 on ~$4 billion of revenue. The valuation therefore rests on whether margins recover once the Eucalyptus integration, branded GLP-1 mix shift and FTC case are behind the company.

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.

Headline figures (approximate, October 2026): HIMS shows revenue (ttm) ~$2.58 billion, q2 2026 revenue ~$753 million (+38% YoY), q2 2026 eps -$0.37 vs ~-$0.05 estimate, net income (ttm) ~-$142 million; HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate.

The bottom line: HIMS vs HNGE

HIMS and HNGE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HIMS and HNGE exposure against your real portfolio. It is not an investment adviser.

Wondering how HIMS or HNGE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Hims & Hers Health

Ask Walnut's AI anything about HIMS and see how it fits what you own.

FAQ

What is the difference between HIMS and HNGE?

+

Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products on a subscription basis. Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HIMS or HNGE the better stock?

+

Neither is universally better. HNGE is the larger incumbent; HIMS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HIMS or HNGE?

+

On forward P/E (as of November 2026), HIMS trades at 39.14x and HNGE at 37.32x, so HNGE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HIMS and HNGE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HIMS vs HNGE?

+

HIMS: The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026 and about 64 percent (adjusted) in the second quarter. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 before acquisitions and branded GLP-1 sales lifted it to ~38 percent in the second quarter, but the company swung to GAAP losses in both quarters, so profitability rather than growth is now the main question. The FTC complaint filed July 29, 2026 and a related securities class action add legal risk, Eucalyptus integration and foreign expansion add execution risk, and the stock has historically fallen much harder than the market in sell-offs. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend. HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~100% one-year gain the stock trades around 33x trailing earnings, 11x sales and 24x book value as of October 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026, adding supply and shaping sentiment.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HIMS or HNGE; figures are approximate and dated (as of November 2026). Verify current data before investing.